AU2013340820A1 - Recombinant particle based vaccines against human cytomegalovirus infection - Google Patents

Recombinant particle based vaccines against human cytomegalovirus infection Download PDF

Info

Publication number
AU2013340820A1
AU2013340820A1 AU2013340820A AU2013340820A AU2013340820A1 AU 2013340820 A1 AU2013340820 A1 AU 2013340820A1 AU 2013340820 A AU2013340820 A AU 2013340820A AU 2013340820 A AU2013340820 A AU 2013340820A AU 2013340820 A1 AU2013340820 A1 AU 2013340820A1
Authority
AU
Australia
Prior art keywords
proteins
cmv
capsid
towne
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013340820A
Other languages
English (en)
Inventor
Corinne John
Christian Schaub
Sabine Wellnitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2013340820A1 publication Critical patent/AU2013340820A1/en
Assigned to PFIZER, INC. reassignment PFIZER, INC. Request for Assignment Assignors: REDVAX GMBH
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
AU2013340820A 2012-10-30 2013-10-30 Recombinant particle based vaccines against human cytomegalovirus infection Abandoned AU2013340820A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12190652.3 2012-10-30
EP12190652 2012-10-30
PCT/EP2013/072717 WO2014068001A1 (en) 2012-10-30 2013-10-30 Recombinant particle based vaccines against human cytomegalovirus infection

Publications (1)

Publication Number Publication Date
AU2013340820A1 true AU2013340820A1 (en) 2015-03-19

Family

ID=47073362

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013340820A Abandoned AU2013340820A1 (en) 2012-10-30 2013-10-30 Recombinant particle based vaccines against human cytomegalovirus infection

Country Status (16)

Country Link
US (1) US20150359879A1 (zh)
EP (2) EP3269388A1 (zh)
JP (1) JP6294890B2 (zh)
KR (1) KR20150076244A (zh)
CN (1) CN104853772A (zh)
AU (1) AU2013340820A1 (zh)
BR (1) BR112015008930A2 (zh)
CA (1) CA2885145A1 (zh)
ES (1) ES2608637T3 (zh)
HK (1) HK1213185A1 (zh)
IL (1) IL237793A0 (zh)
MX (1) MX2015005505A (zh)
PH (1) PH12015500931A1 (zh)
RU (1) RU2015121828A (zh)
SG (1) SG11201501623PA (zh)
WO (1) WO2014068001A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015161926A1 (en) * 2014-04-23 2015-10-29 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
PE20170301A1 (es) * 2014-05-08 2017-03-30 Pfizer Medios y metodos para el tratamiento cmv
AU2015289560B2 (en) * 2014-07-16 2018-09-27 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6724156B2 (ja) 2016-03-16 2020-07-15 アンスティテュ・クリー 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018193307A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
SG11202002174SA (en) * 2017-09-13 2020-04-29 Sanofi Pasteur Human cytomegalovirus immunogenic composition
FR3077490B1 (fr) * 2018-02-02 2022-11-11 Univ Franche Comte Nouvelles compositions vaccinales pour lutter contre le cancer du sein, et procede de preparation
EP3762025A4 (en) * 2018-03-09 2021-12-01 The Regents of the University of California VECTORS OF CMV AND ASSOCIATED USES
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
KR102018341B1 (ko) * 2018-06-21 2019-09-04 성균관대학교산학협력단 RNF170 및 pUL50을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
BR112021006812A2 (pt) 2018-10-17 2021-07-20 Glaxosmithkline Biologicals S.A. proteínas e complexos estabilizados modificados do citomegalovírus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2021108238A1 (en) * 2019-11-26 2021-06-03 Merck Sharp & Dohme Corp. Method for detecting cytomegalovirus (cmv) and measuring and quantifying pentameric complex using an indirect sandwich elisa
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2023223255A1 (en) 2022-05-20 2023-11-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
PL1758609T3 (pl) 2004-06-16 2013-02-28 Glaxosmithkline Biologicals Sa Szczepionka przeciw HPV16 i HPV18 oraz co najmniej jednemu HPV innego typu wybranemu spośród HPV 31, 45 lub 52
EP2144627A1 (en) * 2007-05-11 2010-01-20 Vakzine Projekt Management GmbH Composition containing hcmv particles
AU2009259923B2 (en) * 2008-06-20 2015-09-03 Duke University Compositions, methods and kits for eliciting an immune response
JP2012525133A (ja) * 2009-05-01 2012-10-22 レッドバイオテック・アーゲー 多重遺伝子ベクターによってコードされる組換えウイルス様粒子
GB0907935D0 (en) * 2009-05-08 2009-06-24 Henderson Morley Plc Vaccines
CA2840989A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US9777043B2 (en) * 2011-11-11 2017-10-03 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus

Also Published As

Publication number Publication date
SG11201501623PA (en) 2015-05-28
PH12015500931A1 (en) 2015-06-29
EP2914284A1 (en) 2015-09-09
US20150359879A1 (en) 2015-12-17
JP2015536937A (ja) 2015-12-24
JP6294890B2 (ja) 2018-03-14
EP2914284B1 (en) 2016-09-21
IL237793A0 (en) 2015-05-31
WO2014068001A1 (en) 2014-05-08
HK1213185A1 (zh) 2016-06-30
CN104853772A (zh) 2015-08-19
ES2608637T3 (es) 2017-04-12
CA2885145A1 (en) 2014-05-08
BR112015008930A2 (pt) 2017-11-21
RU2015121828A (ru) 2016-12-20
MX2015005505A (es) 2016-01-08
KR20150076244A (ko) 2015-07-06
EP3269388A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
EP2914284B1 (en) Recombinant particle based vaccines against human cytomegalovirus infection
Anderholm et al. Cytomegalovirus vaccines: current status and future prospects
US20150322115A1 (en) Means and methods for treating cmv
US10300129B2 (en) Epstein-Barr-virus vaccine
US7163685B2 (en) Human cytomegalovirus antigens expressed in MVA and methods of use
AU767460B2 (en) Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
ES2716010T3 (es) Métodos y composiciones para la proteína IL-10 de citomegalovirus
DK2556150T3 (en) A viral particle released after infection of mammalian cells by human cytomegalovirus (HCMV) containing a fusion protein and use thereof
US11844833B2 (en) Expression system for expressing herpesvirus glycoprotein complexes
Cheng et al. Incorporation of GM-CSF or CD40L enhances the immunogenicity of hantaan virus-like particles
US20220143174A1 (en) Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof
JP2024500167A (ja) 増加した免疫原性を有する改変パラポックスウイルス
WO2024003238A1 (en) Epstein-barr-virus vaccine
Deml et al. Virus-like Particles

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PFIZER, INC.

Free format text: FORMER APPLICANT(S): REDVAX GMBH

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application